02/25/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/25/2020. This web page provides information about a new laboratory test kit developed by the Centers for Disease Control and Prevention (CDC) for use in testing patient specimens for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. CDC is also working to develop a new serology laboratory test to assist with efforts to determine how much of the U.S. population has been exposed to SARS-CoV-2. (Text)
02/25/2020 12:00 AM EST
Source: United Kingdom Department of Health (DH). Published: 2/25/2020. This guidance is for suspected cases of COVID-19 (novel coronavirus) where an emergency ambulance response is required. Topics include on-scene clinician precautions, and use of personal protective equipment. This web page links to the guidance, and a separate file for Donning PPE (FFP3 Facemask and Eye Protection). (Text)
02/24/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/24/2020. As part of the risk assessment and public health management of persons with potential COVID-19 (novel coronavirus), public health personnel will typically conduct interviews and assess these individuals for fever or other symptoms of COVID-19. In certain circumstances they will also obtain respiratory specimens. This guidance is intended to address recommended infection prevention and control practices when these activities are performed at a home or non-home residential settings, which warrant additional considerations beyond those described for healthcare settings. (Text)
02/24/2020 12:00 AM EST
Source: World Health Organization (WHO). Published: 2/24/2020. This 11-page document has been prepared based on the evidence currently available about coronavirus disease 2019 (COVID-19) transmission (human-to-human transmission via respiratory droplets or direct contact from an infected individual), and is recommended for use in conjunction with the World Health Organization (WHO) Handbook for Management of Public Health Events on Board Ships. It is for any authority involved in public health response to a COVID-19 public health event on board ships, including International Health Regulations (IHR) National Focal Point (NFP); port health authorities; local, provincial, and national health surveillance and response systems; port operators; and ship operators. (PDF)
02/23/2020 12:00 AM EST
Source: European Union, European Centre for Disease Prevention and Control (ECDC). Published: 2/23/2020. This five-page report details the limited information currently available about the different COVID-19 clusters of cases in four regions in Italy. The risk associated with COVID-19 infection for people from the European Union/European Economic Area (EU/EEA) and United Kingdom is currently considered to be low to moderate, but the risk assessment for the EU/EEA might change when more data become available. The risk of the occurrence of similar clusters, similar to the ones in Italy, associated with COVID-19 in other countries in the EU/EEA and the UK is currently considered to be moderate to high. (PDF)
02/22/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/22/2020. This web page answers frequently asked questions about coronavirus disease (COVID-19) and children. The information provided includes that there is no evidence that children are more susceptible, and that there have been very few reports of the clinical outcomes for children with COVID-19 to date. (Text)
02/21/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/21/2020. This guidance, updated on February 21, 2020, is based on the currently limited information available about the coronavirus disease 2019 (COVID-19) related to disease severity, transmission efficiency, and shedding duration. This cautious approach will be refined and updated as more information becomes available and as response needs change in the United States. This guidance is applicable to all U.S. healthcare settings. This guidance is not intended for non-healthcare settings (e.g., schools) or to persons outside of healthcare settings. (Text)
02/21/2020 12:00 AM EST
Source: Henry J. Kaiser Family Foundation. Published: 2/21/2020. This tracker, updated on February 21, 2020, provides the number of cases and deaths from novel coronavirus by country, the trend in case and death counts by country, and a global map showing which countries have cases and deaths. It should be noted that the World Health Organization reported case numbers are conservative, and likely represent an undercount of the true number of coronavirus cases, especially in China. This tracker will be updated regularly, as new situation reports are released. (Text)
02/21/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/21/2020. This web page for healthcare professionals, updated on February 21, 2020, provides answers to frequently asked questions about the 2019 novel coronavirus (COVID-19). Topics includes the clinical features of COVID-19, who is at risk, which body fluids can spread infection, how healthcare personnel should protect themselves when evaluating a patient who may have COVID-19, and how to treat a COVID-19 infection. (Text)
02/21/2020 12:00 AM EST
Source: Imperial College London. Published: 2/21/2020. This six-page document is Report 6 of a series of reports from Imperial College London on COVID-19. It analyzed COVID-19 cases exported from mainland China to different regions and countries, comparing the country-specific rates of detected and confirmed cases per flight volume to estimate the relative sensitivity of surveillance in different countries. (PDF)
02/21/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/21/2020. This web page provides tips and guidance for public health officials to help counter stigma during the novel coronavirus (COVID-19) response, including that they can communicate the fact that being Chinese or Asian American does not increase the chance of getting or spreading COVID-19. Stigma and discrimination can occur when people associate an infectious disease, such as COVID-19, with a population or nationality, even though not everyone in that population or from that region is specifically at risk for the disease. (Text)
02/20/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention (CDC). Published: 2/20/2020. The purpose of this three-page document is to provide official diagnosis coding guidance for health care encounters and deaths related to the 2019 novel coronavirus (COVID-19), previously named 2019-nCoV. The ICD-10-CM codes provided in this document are intended to provide information on the coding of encounters related to coronavirus. Other codes for conditions unrelated to coronavirus may be required to fully code these scenarios. (PDF)
02/19/2020 12:00 AM EST
Source: Public Health Agency of Canada (PHAC). Published: 2/19/2020. Healthcare professionals should refer to this five-page 2019 novel coronavirus (COVID-19) case report form to aid with the detection and reporting of COVID-19 in Canada. Its requests include case information, symptoms, pre-existing conditions and risk factors, exposures, and clinical evaluations, complications, and diagnoses. (PDF)
02/19/2020 12:00 AM EST
Source: Harvard University, Harvard T.H. Chan School of Public Health. Published: 2/19/2020. Amid new diagnostic methods, reports of a surge in deaths and new cases of the coronavirus disease (COVID-19) in China have sparked more questions about the outbreak. With the situation rapidly changing, The World’s Elana Gordon and Harvard Chan’s Michael Mina took questions and provided information during this 31-minute Facebook Live event. (Video or Multimedia)
02/19/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/19/2020. This web page provides specific guidance for the collection and submission of postmortem specimens from deceased persons under investigation (PUI) for COVID-19 (novel coronavirus). It also provides recommendations for biosafety and infection control practices during specimen collection and handling, including during autopsy procedures. The guidance can be utilized by medical examiners, coroners, pathologists, other workers involved in the postmortem care of deceased PUI, and local and state health departments. (Text)
02/18/2020 12:00 AM EST
Source: Office of the Assistant Secretary for Preparedness and Response [U.S. Department of Health and Human Services] (HHS ASPR). Published: 2/18/2020. This web page, updated on February 18, 2020, describes how the Office of the Assistant Secretary for Preparedness and Response is working with partners to explore the development of new medical countermeasures and take other actions to enhance health security about the 2019 novel coronavirus (COVID-19). Tabs link to pages about COVID-19 MCM Market Research Initiative; EZ BAA for COVID-19 Diagnostics; 2019 Novel Coronavirus Stakeholder Listening Session Transcript; Public Health Emergency Declaration; and CDC Information for Healthcare and Public Health Professionals. (Text)
02/18/2020 12:00 AM EST
Source: National Ebola Training and Education Center (NETEC). Published: 2/18/2020. This 18-minute video provides guidance for the donning and doffing of personal protective equipment (PPE) for COVID-19 (2019 novel coronavirus/2019-nCoV) following the Centers for Disease Control and Prevention guidelines for standard precautions, contact precautions, airborne precautions, and eye protection. It provides information about pathogenic organism, reservoir, portal of exit, mode of transmission, portal of entry, and susceptible host. (Video or Multimedia)
02/18/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/18/2020. This web page provides guidance for ships originating from, or stopping in, the United States to help prevent, detect, and medically manage suspected COVID-19 (2019 novel coronavirus) infections. It includes guidance for preventing spread of COVID-19 during and after a voyage, including personal protective measures for crew members. As ships travel worldwide, ship management and medical staff need to be aware and respond to local jurisdictional requirements. (Text)
02/18/2020 12:00 AM EST
Source: National Institute for Occupational Safety and Health [Centers for Disease Control and Prevention] (CDC NIOSH). Published: 2/18/2020. This web page highlights resources that may help prevent workplace exposures to acute respiratory illnesses, including the 2019 novel coronavirus (COVID-19). Guidance and resources are provided for these topics: Businesses; Healthcare Settings; Laboratories; Transportation; Personal Protective Equipment Resources; and Other Resources. (Text)
02/18/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/18/2020. This web page provides answers to frequently asked questions about healthcare infection prevention and control for the novel coronavirus (COVID-19), including about personal protective equipment. It is for healthcare personnel who may care for patients who are confirmed with or under investigation for COVID-19, and supports the existing Healthcare Infection Prevention and Control Guidance for COVID-19. It will assist healthcare facilities in preventing transmission of COVID-19 in healthcare settings. (Text)
02/18/2020 12:00 AM EST
Source: American Bar Association (ABA). Published: 2/18/2020. This one-hour, 29-minute webinar provides an overview of the global and U.S. situation for the 2019 novel coronavirus (COVID-19), as well as public health planning considerations for state, tribal, local, and territorial health departments. Legal experts discuss best practices for legal preparedness and describe vital legal concepts such as disease surveillance and reporting requirements, non-pharmaceutical interventions, and social distancing measures. It is the first webinar in a two-part webinar series on Healthcare and Public Health Legal Preparedness, co-hosted by the American Bar Association, Centers for Disease Control and Prevention’s Public Health Law Program and Center for Preparedness and Response, National Governors Association (NGA), Association of Healthcare Emergency Preparedness Professionals (AHEPP), and American Health Lawyers Association (AHLA). (Video or Multimedia)
02/16/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/16/2020. This guidance, updated on February 16, 2020, is intended to serve as a framework for disposition of hospitalized patients with 2019 novel coronavirus (COVID-19). All patients should be evaluated on a case-by-case basis, and their disposition discussed with health care providers and public health departments. The page lists considerations for Hospitalized Patients with COVID-19 Under Transmission-Based Precautions, and Disposition of Hospitalized Patients with COVID-19. (Text)
02/16/2020 12:00 AM EST
Source: World Health Organization (WHO). Published: 2/16/2020. This web page provides coronavirus disease (COVID-19) technical guidance for points of entry and mass gatherings, with documents written specifically for COVID-19, and general public health preparedness and response guidance. (Text)
02/15/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/15/2020. This web page, updated on February 15, 2020, provides guidance and recommendations for preparing for and responding to patients with confirmed or possible coronavirus 2019 (COVID-19) infection. Recommendation topics are 911 Public Safety Answering Points (PSAPs), Modified Caller Queries, Emergency Medical Services (EMS) Clinicians and Medical First Responders, Personal Protective Equipment (PPE), EMS Transport of a Person Under Investigation (PUI) or Patient with Confirmed 2019-nCoV to a Healthcare Facility (including interfacility transport), Cleaning EMS Transport Vehicles after Transporting a PUI or Patient with Confirmed 2019-nCoV, Follow-up and/or Reporting Measures by EMS Clinicians After Caring for a PUI or Patient with Confirmed 2019-nCoV, and EMS Employer Responsibilities. (Text)
02/15/2020 12:00 AM EST
Source: Imperial College London. Published: 2/15/2020. This seven-page document is Report 5 of a series of reports from Imperial College London on COVID-19. It describes how genetic diversity of SARS-CoV-2, the virus which causes COVID-19, provides information about epidemic origins and the rate of epidemic growth. By analyzing 53 SARS-CoV-2 whole genome sequences collected up to February 3, 2020, the analysis finds a strong association between the time of sample collection and accumulation of genetic diversity. (PDF)
02/15/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/15/2020. This web page describes one important way that the Centers for Disease Control and Prevention (CDC) is supporting global efforts to study and learn about the virus that causes COVID-19 (novel coronavirus) in the laboratory, which is growing the virus in cell-culture so that researchers in the scientific and medical community can use the virus in their studies. CDC’s SARS-CoV-2 isolate can eventually be requested by public and academic institutions that maintain appropriate facilities and safety programs, as well as have the appropriate expertise. (Text)
02/14/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/14/2020. This web page, updated on February 14, 2020, provides information about the outbreak caused by a novel (new) coronavirus first identified in Wuhan, China, under these topics: Situation Summary; What You Need to Know about 2019-nCoV; Information for Travelers; Information for Healthcare Professionals; Information for Laboratories; Information for Public Health Professionals; Information for Businesses; Risk Assessment; and News on 2019-nCoV. (Text)
02/14/2020 12:00 AM EST
Source: U.S. Food and Drug Administration (FDA). Published: 2/14/2020. While respiratory viruses, in general, are not known to be transmitted by implantation, transplantation, infusion, or transfer of human cells, tissues, or cellular or tissue-based products (HCT/Ps), the potential for transmission of COVID-19 (2019 novel coronavirus) by HCT/Ps is unknown at this time. According to this information from the Food and Drug Administration (FDA), there have been no reported cases of transmission of COVID-19 via these products. The FDA will continue to monitor the situation and will issue updates as information becomes available. (Text)
02/14/2020 12:00 AM EST
Source: National Ebola Training and Education Center (NETEC). Published: 2/14/2020. This web page provides three guidance documents for COVID-19 (2019 novel coronavirus) personal protective equipment (PPE): COVID-19: PPE Donning and Doffing; PPE Competency Validation Checklist; and PPE Competency Validation Checklist - Instructor Guide. It also provides links to Contaminated Glove Removal instructions, and a just in time training video on Personal Protective Equipment for the 2019 Novel Coronavirus (COVID-19). (Text)
02/14/2020 12:00 AM EST
Source: Tulane University. Published: 2/14/2020. This one-hour, 45-minute panel discussion on the novel coronavirus (COVID-19) features experts who describe the origins of the virus and viral ecology; the clinical disease; epidemiological modeling and projections; the international response to diseases like coronavirus; hospital plans for isolation and diagnostics; and Tulane University's response. (Video or Multimedia)
02/14/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention (CDC). Published: 2/14/2020. This one-page algorithm details the risk assessment and public health management decision-making for possible cases of coronavirus disease 2019 (COVID-19), with each question referring to within the past 14 days. It details actions to take for high risk, medium risk, low risk, and no identifiable risk. (PDF)
02/14/2020 12:00 AM EST
Source: Center for Health Security [Johns Hopkins University, Bloomberg School of Public Health]. Published: 2/14/2020. Because of the constraints of ventilator availability, public health planners may find the information in this one-page fact sheet useful when preparing hospitals for severe cases of COVID-19 that will require mechanical ventilation. To meet a potential surge in demand, the Centers for Disease Control and Prevention Strategic National Stockpile (SNS) stores and maintains mechanical ventilators that can be deployed on request through appropriate channels. (PDF)
02/13/2020 12:00 AM EST
Source: ADA [Americans with Disabilities Act] National Network. Published: 2/13/2020. In this one-hour, 27-minute webinar, emergency managers from city, county, and state levels and the Federal Emergency Management Agency (FEMA)'s Region IX Disability Integration Specialist discuss how they were able to build better plans and engage with the disability community to achieve whole community all hazards emergency plans. They discuss why municipalities should build an inclusive all hazards plan, and why they should include people with disabilities in the planning process. (Video or Multimedia)
02/12/2020 12:00 AM EST
Source: World Health Organization (WHO). Published: 2/12/2020. This web page, updated on February 12, 2020, provides a seven-page document whose purpose is to provide interim guidance to laboratories and stakeholders involved in laboratory testing of patients who meet the definition of suspected case of pneumonia associated with a novel coronavirus (COVID-19) identified in Wuhan, China. It also provides information about molecular testing of COVID-19; and WHO appointed COVID-19 referral laboratories and procedures. (Text)
02/12/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/12/2020. This interim guidance may help prevent workplace exposures to acute respiratory illnesses, including COVID-19 (2019 novel coronavirus), in non-healthcare settings. The guidance also provides planning considerations if there are more widespread, community outbreaks of COVID-19. Topics include recommended strategies for employers to use now, and important considerations for creating an infectious disease outbreak response plan. (Text)
02/11/2020 12:00 AM EST
Source: Government of Canada. Published: 2/11/2020. This web page outlines surveillance case definitions for COVID-19 (2019 novel coronavirus) and provides instructions on reporting to the national level. It also provides information about exposure criteria and factors that raise the index of suspicion that should also be considered. (Text)
02/11/2020 12:00 AM EST
Source: Aspen Institute. Published: 2/11/2020. In this one-hour, 22-minute panel discussion, experts with experience in the SARS, Ebola, and Zika outbreaks detail the emerging novel coronavirus (COVID-19) and the threat it poses. They discuss how bad it may get, how dangerous is it, and if the country is prepared for it. (Video or Multimedia)
02/10/2020 12:00 AM EST
Source: Government of Canada. Published: 2/10/2020. These guidelines outline the recommended goals, objectives, and activities for surveillance of human infection with COVID-19 (2019 novel coronavirus) in Canada. The primary goal of the public health response in Canada is early detection and containment; the secondary objective is to characterize the clinical and epidemiologic features of COVID-19 in order to better inform prevention and control efforts. (Text)
02/10/2020 12:00 AM EST
Source: Imperial College London. Published: 2/10/2020. This 12-page document is Report 4 of a series of reports from Imperial College London on COVID-19. It presents case fatality ratio (CFR) estimates for three strata of COVID-19 (novel coronavirus) infections. It is important to note that the differences in these estimates do not reflect underlying differences in disease severity between countries. CFRs seen in individual countries will vary depending on the sensitivity of different surveillance systems to detect cases of differing levels of severity and the clinical care offered to severely ill cases. (PDF)
02/08/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/8/2020. This interim guidance for U.S.-bound travelers and people located in the United States who may have been exposed to the 2019 novel coronavirus (2019-nCoV), updated on February 8, 2020, was created to provide U.S. public health authorities and other partners with a framework for assessing and managing risk of potential exposures to 2019-nCoV, and implementing public health actions based on a person’s risk level and clinical presentation. It is effective as of February 3, 2020, and does not apply retrospectively to people who have been in China during the previous 14 days and are already in the United States, or those being managed as part of a contact investigation. (Text)
02/08/2020 12:00 AM EST
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 2/8/2020. Based on the current coronavirus disease 2019 (COVID-19) situation and availability of personal protective equipment (PPE), the Centers for Disease Control and Prevention has these specific recommendations. Topics on this web page are Who Needs PPE; Who Does Not Need PPE; Manufacturers and Distributors; Strategies for Optimizing Supply of N95 Respirators; and Frequently Asked Questions About Respirators and Their Use. (Text)
02/07/2020 12:00 AM EST
Source: Public Health Agency of Canada (PHAC). Published: 2/7/2020. This interim guidance is for federal/provincial/territorial (F/P/T) public health authorities (PHA) in the event that a case of human illness caused by a novel coronavirus (COVID-19) is suspected or confirmed within their jurisdictions. The strategy outlined in this guidance is containment (i.e., to reduce opportunities for transmission to contacts in the community) and is based on the assumption that the virus is primarily spread while the case is symptomatic. (Text)
Blame and Discrimination Attached to 2019-nCoV: An FAQ for U.S. Elected Leaders and Health Officials
02/05/2020 12:00 AM EST
Source: Center for Health Security [Johns Hopkins University, Bloomberg School of Public Health]. Published: 2/5/2020. This two-page fact sheet answers frequently asked questions about blame and discrimination attached to 2019-nCoV (COVID-19), including what social stigma is in the context of a disease outbreak, and what political and health leaders can do to prevent stigmatization of people of Asian descent during the COVID-19 outbreak. (PDF)
02/04/2020 12:00 AM EST
Source: Federal Aviation Administration (FAA). Published: 2/4/2020. This four-page safety alert provides interim health guidance for the 2019 novel coronavirus (COVID-19) for U.S.-based flight and cabin crew members while in China; U.S. and third country-based flight and cabin crew members upon arrival to the United States within 14 days of travel to, from, or within China; China-based flight and cabin crew members while in the U.S.; U.S. air carriers housing flight and cabin crews while in China; and U.S. air carriers supervising self-monitoring of flight and cabin crews who have had layovers in China. (PDF)
02/04/2020 12:00 AM EST
Source: Public Health Agency of Canada (PHAC). Published: 2/4/2020. This interim infection prevention and control guidance is based upon Canadian guidance developed for previous coronavirus outbreaks (e.g., MERS and SARS), as well as interim guidance for COVID-19 (2019 novel coronavirus) published by the World Health Organization (WHO). The 18 recommended infection prevention and control measures include Screening and Assessment; Public Health Surveillance and Notification; and Laboratory Testing and Reporting. (Text)
02/01/2020 12:00 AM EST
Source: Office of the Assistant Secretary for Preparedness and Response [U.S. Department of Health and Human Services] (HHS ASPR). Published: 2/2020. This Topic Collection from TRACIE (Technical Resources, Assistance Center, and Information Exchange), updated in February 2020, provides resources that discuss competencies for disaster medicine; experiences with different methods and models for health professional training and workforce development; selected general training resources to support all-hazards preparedness; tools to support training and workforce development; and considerations related to U.S. workforce development, including research on training's effects on willingness to work during a disaster. (Text)
02/01/2020 12:00 AM EST
Source: Occupational Safety and Health Administration [U.S. Department of Labor] (OSHA). Published: 2/2020. This web page provides information for workers and employers about the evolving coronavirus outbreak first identified in Wuhan City, Hubei Province, China. It includes links to interim guidance and other resources for preventing exposures to, and infection with, 2019 novel coronavirus (2019-nCov). Guidance information is provided for Hazard Recognition, Standards, Medical Information, Control and Prevention, Background, and Additional Resources. (Text)
02/01/2020 12:00 AM EST
Source: World Health Organization, Regional Office for the Western Pacific. Published: 2/2020. In response to the novel coronavirus (COVID-19) outbreak, this 10-page risk communication package for healthcare facilities provides healthcare workers and healthcare facility management with the information, procedures, and tools required to safely and effectively work. The package contains a series of simplified messages and reminders based on the World Health Organization's more in-depth technical guidance on infection prevention and control in healthcare facilities in the context of COVID-19. (PDF)
02/01/2020 12:00 AM EST
Source: National Institute for Occupational Safety and Health [Centers for Disease Control and Prevention] (CDC NIOSH). Published: 2/2020. This one-page infographic details the differences between surgical masks and N95 respirators with regard toTesting and Approval, Intended Use and Purpose, Face Seal Fit, Fit Testing Requirement, User Seal Check Requirement, Filtration, Leakage, and Use Limitations. (PDF)
01/31/2020 12:00 AM EST
Source: World Health Organization (WHO). Published: 1/31/2020. This two-page document, updated on January 31, 2020, provides guidance to Member States on implementation of global surveillance of 2019-nCoV. The objectives of this global surveillance are to monitor trends of the disease where human-to-human and/or zoonotic transmission occurs; rapidly detect new cases in countries where the virus is not circulating; provide epidemiological information to conduct risk assessment at the national, regional, and global level; and provide epidemiological information to guide response measures. This page also provides links to a template for line listing in Excel format, and data dictionary in Excel format in English, Chinese, French, and Russian. (PDF)
01/27/2020 12:00 AM EST
Source: World Health Organization (WHO). Published: 1/27/2020. This 16-page document details the objectives of a consultation held on January 24, 2020, on candidate therapeutic agents for use in novel coronavirus (COVID-19) infection: to outline criteria that could inform the evidence-based selection of therapeutic agents for clinical trials; review and critically appraise the existing evidence regarding different investigational therapeutics agents; and decide on the more promising candidate therapeutics, based on currently available evidence that can be evaluated in humans infected with COVID-19 to reduce mortality and disease progression. (PDF)
01/25/2020 12:00 AM EST
Source: Imperial College London. Published: 1/25/2020. This five-page document is Report 3 of a series of reports from Imperial College London on COVID-19. It details how self-sustaining human-to-human transmission of the novel coronavirus (COVID-19) is the only plausible explanation of the scale of the outbreak in Wuhan, China. The analysis indicates that it is highly likely that the human-to-human transmissibility of COVID-19 is sufficient to support sustained human transmission unless effective control measures are implemented. (PDF)
01/22/2020 12:00 AM EST
Source: Imperial College London. Published: 1/22/2020. This six-page document is Report 2 of a series of reports from Imperial College London on COVID-19, and updates Report 1. Since then, cumulative confirmed cases reported by the Chinese authorities have increased 10-fold. The analysis suggests that the novel coronavirus (COVID-19) outbreak has caused substantially more cases of moderate or severe respiratory illness in Wuhan than have currently been detected. (PDF)
01/17/2020 12:00 AM EST
Source: World Health Organization (WHO). Published: 1/17/2020. This 22-page report summarizes an initiative to map available and pipeline diagnostics against antibacterial resistance (ABR), identify gaps in the availability of such diagnostics in low- and middle-income countries, and establish a research and development (R&D) priority list of diagnostics against ABR for the next three to five years. This mapping and list of gaps and priorities provided the basis for developing these consensus target product profiles (TPPs) for the highest-priority diagnostics on the R&D priority list. (PDF)
01/17/2020 12:00 AM EST
Source: Imperial College London. Published: 1/17/2020. This four-page document is Report 1 of a series of reports from Imperial College London on COVID-19. It estimates the potential number of COVID-19 cases in Wuhan City, China, as of January 17, 2020, and concludes that it is likely that the Wuhan outbreak of the novel coronavirus has caused substantially more cases of moderate or severe respiratory illness than currently reported. (PDF)
04/15/2019 12:00 AM EDT
Source: Association of Healthcare Emergency Preparedness Professionals (AHEPP). Published: 4/15/2019. During this one-hour, two-minute presentation, the speaker discusses the different types of radiologic events and the response issues that they generate, reviews the distinction between radiation contamination and radiation illness and the specific issues of each, and discusses key issues for medical response to radiation emergencies. The webinar also covers reactor events, including the Fukushima event in Japan; radiological dispersal device events; and nuclear detonation events. (Video or Multimedia)
04/11/2019 12:00 AM EDT
Source: University of Nebraska Medical Center (UNMC). Published: 4/11/2019. Upon completion of this 15-minute module, learners will be able to differentiate between engineering and administrative controls to prevent the spread of infection in a variety of situations. Given a high-level isolation scenario, participants will learn how to utilize both engineering and administrative controls to safely solve a series of problems. (Video or Multimedia)
.png)
No hay comentarios:
Publicar un comentario